2024

1. Efficacy and safety of regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study

   Journal of Gastrointestinal Oncology, Vol. 15, Núm. 3, pp. 1072-1081